Holocene

Black & Veatch IgniteX Carbon Dioxide Removal Accelerator Program Selects 6 Startups

Retrieved on: 
月曜日, 6月 3, 2024

As new reports of a record spike in atmospheric carbon dioxide levels intensify climate change concerns, Black & Veatch has selected six startups to participate in its BV IgniteX Carbon Dioxide Removal (CDR) Accelerator – a provider of support to enterprises on the cutting edge of climate technology.

Key Points: 
  • As new reports of a record spike in atmospheric carbon dioxide levels intensify climate change concerns, Black & Veatch has selected six startups to participate in its BV IgniteX Carbon Dioxide Removal (CDR) Accelerator – a provider of support to enterprises on the cutting edge of climate technology.
  • The program culminates with a showcase where the entrepreneurs present their solutions and outline their value propositions and market opportunity.
  • Ebb Carbon is pioneering a new marine carbon dioxide removal solution by enhancing the ocean’s natural ability to safely store CO2 with an electrochemical technology.
  • Black & Veatch is teaming up with RTI International – a leading independent research institute – to provide technical and commercialization support to program participants.

EQS-News: CPI PROPERTY GROUP publishes financial results for the first quarter of 2024

Retrieved on: 
土曜日, 6月 1, 2024

CPI PROPERTY GROUP (“CPIPG” or the “Group”), a leading European landlord, hereby publishes unaudited financial results for the three-month period ending 31 March 2024.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG” or the “Group”), a leading European landlord, hereby publishes unaudited financial results for the three-month period ending 31 March 2024.
  • The Group has closed more than €600 million of disposals year-to-date (€340 million in Q1 2024).
  • In addition, more than €600 million of signed disposals are expected to close in the coming months.
  • Net LTV is 49.7% pro forma only for disposals closed post-reporting date or to be closed in the coming months.

Okeanis Eco Tankers Corp. – Unaudited Condensed Financial Statements for the First Quarter and Three-Month Period of 2024

Retrieved on: 
木曜日, 5月 16, 2024

ATHENS, Greece, May 16, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “Company” or “OET” or “Okeanis”) (NYSE:ECO / OSE:OET), today reported unaudited condensed financial statements for the first quarter and three-month period of 2024, which are attached to this press release.

Key Points: 
  • ATHENS, Greece, May 16, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “Company” or “OET” or “Okeanis”) (NYSE:ECO / OSE:OET), today reported unaudited condensed financial statements for the first quarter and three-month period of 2024, which are attached to this press release.
  • Adjusted profit and Adjusted earnings per share (non-IFRS measures*) for the period of $39.6 million or $1.23 per basic & diluted share.
  • Fleetwide daily TCE rate of $63,600 per operating day; VLCC and Suezmax TCE rates of $68,800 and $56,700 per operating day, respectively.
  • OET will be hosting a conference call and webcast at 13:30 CET on Thursday May 16, 2024, to discuss the Q1 2024 results.

Aqua Metals Advances Circular Supply Chain Strategy with Sierra ARC Buildout, Commercial Partnerships, and $40M Capital Infusion, Reports First Quarter 2024 Results

Retrieved on: 
水曜日, 5月 15, 2024

This capital infusion is expected to complete Phase One of the Sierra ARC buildout and commissioning in 2024.

Key Points: 
  • This capital infusion is expected to complete Phase One of the Sierra ARC buildout and commissioning in 2024.
  • Enhanced Sierra ARC feedstock and offtake diversity and economics through additional agreements with black mass producers.
  • “We expect to expand and solidify the circular supply chain to provide lower-cost, decarbonized critical materials to create truly sustainable and domestically produced Li-ion batteries.
  • The webcast replay will also be available in the “News / Events” section of the Aqua Metals website.

Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 5月 15, 2024

The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.

Key Points: 
  • The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.
  • General and administrative expenses increased to $2,627,076 in the first quarter of 2024 from $2,335,984 in the first quarter of 2023.
  • Operations expenses increased to $1,102,193 in the first quarter of 2024 compared to $878,518 in the first quarter of 2023.
  • Sales and marketing expenses increased to $739,734 in the first quarter of 2024 from $370,237 in the first quarter of 2023.

Evoke Pharma Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 14, 2024

SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2024, and recent corporate developments.

Key Points: 
  • SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2024, and recent corporate developments.
  • Matt D’Onofrio, CEO of Evoke Pharma commented, “The results achieved in the first quarter of 2024 reflect continued momentum with the adoption of GIMOTI.
  • For the first quarter of 2024, selling, general and administrative expenses were approximately $3.1 million compared to $2.8 million for the first quarter of 2023.
  • Evoke reiterates its net revenue guidance in 2024 of approximately $14 million.

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
火曜日, 5月 14, 2024

The Company plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024.

Key Points: 
  • The Company plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024.
  • Preliminary data from the study are anticipated during the fourth quarter of 2024 or first quarter of 2025, depending on patient enrollment and study site activation.
  • Based on ADI-270’s promising profile in preclinical studies to date, Adicet expects to submit an IND for ADI-270 in renal cell carcinoma in the second quarter of 2024.
  • Financial Results for First Quarter 2024:
    Research and Development (R&D) Expenses: R&D expenses were $23.9 million for the three months ended March 31, 2024, compared to $26.8 million during the same period in 2023.

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 5月 9, 2024

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET Today
    SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2024.
  • “Building on the positive momentum from the first PATHFNDR readout in 2023, Crinetics began 2024 with continued strong performance.
  • We plan to report initial results from a subset of patients from these trials in the second quarter,” continued Dr. Struthers.
  • In March, Crinetics reported positive topline results from its placebo-controlled Phase 3 study of paltusotine in non-pharmacologically treated participants with acromegaly.

Armada Hoffler Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024

VIRGINIA BEACH, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter ended March 31, 2024 and provided an update on current events and earnings guidance.

Key Points: 
  • VIRGINIA BEACH, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter ended March 31, 2024 and provided an update on current events and earnings guidance.
  • Maintained the Company's previous guidance range for 2024 full-year Normalized FFO of $1.21 to $1.27 per diluted share.
  • Third-party construction backlog as of March 31, 2024 was $343.4 million and construction gross profit for the first quarter was $4.1 million.
  • During the first quarter of 2024, unrealized gains on non-designated interest rate derivatives that positively affected FFO were $6.5 million.

Brightcove Announces Financial Results for First Quarter Fiscal Year 2024

Retrieved on: 
水曜日, 5月 8, 2024

Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the first quarter ended March 31, 2024.
  • First Quarter 2024 Financial Highlights:
    Revenue for the first quarter of 2024 was $50.5 million, an increase of 3% compared to $49.1 million for the first quarter of 2023.
  • Income (loss) from operations was $2.0 million for the first quarter of 2024, compared to ($10.7) million for the first quarter of 2023.
  • Brightcove earnings will be streamed on May 8, 2024, at 5:00 p.m. (Eastern Time) to discuss the Company's financial results and current business outlook.